NCT05248685撤回1 期
Single-center, Open-Label, Non-randomized, Single-Arm Phase 1 Study to Evaluate the Safety and Tolerability of Optimized Dual CD33/CLL1 CAR T Cells in Subjects With Refractory or Relapsed Acute Myeloid Leukemia
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 撤回
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Incidence and severity of adverse events (AE)
研究概览
简要总结
This is a single-center, open-label, non-randomized, single-arm Phase 1 Study to evaluate safety and tolerability of optimized Dual CD33/CLL1 CAR T Cells in subjects with refractory or relapsed acute myeloid leukemia. Maximum of twenty subjects will be enrolled. After the collection of PBMC and about 5 days before infusion, lymphodepletion chemotherapy (fludarabine at 30 mg/m^2/day and cyclophosphamide at 250 mg/m^2/day) will be administrated for 3 days.
Then this study will be using BOIN1/2 approach from starting dose 1: 1×10^6 (±20%) to dose 2: 5×10^6 (±20%). If the manufactured cells were not sufficient to meet the preassigned standard dose criteria, patients are given infusion at a low dose of 5×10^5 (±20%) /kg.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 1 Year 至 70 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •In order to be eligible to participate in this study, an individual must meet all of the following criteria:
- •Co-expression of tumor surface antigens CD33 and CLL1 was confirmed (among which, the proportion of cells expressing CD33 was ≥ 80%; and the proportion of cells expressing CLL1 ≥ 80%); patients with primary drug resistance, chemotherapy relapse, extramedullary relapse, persistent residual disease positive or relapsed/refractory acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation;
- •Male or female, aged 1-70 years;
- •No serious allergic constitution;
- •Eastern Cooperative Oncology Group (ECOG) performance status (Oken et al., 1982) score 0 to 2;
- •Have life expectancy of at least 60 days based on investigator's judgement;
- •Provide a signed informed consent before any screening procedure; subjects who voluntarily participate in the study should have the ability to understand and sign the informed consent form and be willing to follow the study visit schedule and relevant study procedure, as specified in the protocol. Candidates aged 19-70 years need to be sufficiently conscious and able to sign the treatment consent form and voluntary consent form; Children candidates of 8-18 years old need to be sufficiently conscious and able to sign the treatment consent form and voluntary consent form and their legal guardian or patient advocate has also need to sign the treatment consent form and voluntary consent form, respectively.Children candidates of 1-7 can be recruited after the legal guardian or patient advocate has signed the treatment consent form and voluntary consent form.
排除标准
- •An individual who meets any of the following criteria will be excluded from participation in this study:
- •Intracranial hypertension or disorder of consciousness;
- •Symptomatic heart failure or severe arrhythmia;
- •Symptoms of severe respiratory failure;
- •Complicated with other types of malignant tumors;
- •Diffuse intravascular coagulation;
- •Serum creatinine and / or blood urea nitrogen ≥ 1.5 times of the normal value;
- •Suffering from septicemia or other uncontrollable infections;
- •Patients with uncontrollable diabetes;
- •Severe mental disorders;
- •Obvious and active intracranial lesions were detected by cranial magnetic resonance imaging (MRI);
- •Have received organ transplantation (excluding bone marrow transplant);
- •Reproductive-aged female patients with positive blood HCG test;
- •Screened to be positive of infection of hepatitis (including hepatitis B and C), AIDS or syphilis;
- •For patients with CAR-T cells derived from autologous lymphocytes, leukemia blasts accounted for more than 30% of all cells in peripheral blood;
- •Patients unable to provide a transplant donor about 30 days after the CAR-T cell transfusion.
研究组 & 干预措施
Dual CD33/CLL1 CAR T
Experimental
All patients who receive Dual CD33/CLL1 CAR T Cell infusion
干预措施: Dual CD33/CLL1 CAR T (Biological)
结局指标
主要结局
Incidence and severity of adverse events (AE)
时间窗: 30 days post intravenous injection
Dose limiting toxicity (DLT)
时间窗: 21 days post intravenous injection
DLT assessment according to the clinical study protocol
次要结局
- Objective response rate (ORR)(28 days post infusion)
- Concentration of PK CAR positive T cells in peripheral blood(30 days post infusion)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
1 期
Gemcitabine Combined With Apatinib and Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma.Nasopharyngeal CarcinomaNCT04073784Sun Yat-sen University41
已完成
1 期
A Study to Evaluate the Safety and Efficacy of SHR-1210, Gemcitabine and Cis-platinum by R/M NPC SubjectsNasopharyngeal CarcinomaNCT03121716Jiangsu HengRui Medicine Co., Ltd.23
招募中
1 期
NKG2D/CLDN18.21 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid TumorPancreatic CancerSolid TumorGastric CancerNCT06134960Peking University12
招募中
早期 1 期
NKG2D/CLDN18.2 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid TumorsSolid TumorPancreatic CancerGastric CancerNCT05583201jianming xu18
招募中
早期 1 期
NKG2D CAR-T(KD-025) in the Treatment of Advanced NKG2DL+ Solid TumorsSolid TumorCRCNCT05382377jianming xu18